5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition
    Meeting Abstract

    Hitchman, T. D.; Ceraudo, E.; Moore, A. R.; Shoushtari, A. N.; Francis, J. H.; Guan, Y.; Chen, J.; Chang, M. T.; Taylor, B. S.; Sakmar, T. P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype
    Meeting Abstract

    Zhu, H.; Oba, J.; Yu, X.; Creasy, C. A.; Forget, M. A.; Carapeto, F.; Haymaker, C. L.; Wu, C. J.; Karpinets, T. V.; Wang, W. L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Disparities in work status after treatment for breast cancer: A controlled, longitudinal study
    Meeting Abstract

    Blinder, V. S.; Patil, S.; Eberle, C.; Jung, G.; Kampel, L. J.; Hwang, C.; Bao, T.; Robson, M. E.; Malik, M.; Gany, F.
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • Diversity of enrollment in prostate cancer clinical trials: Current status and future directions
    Meeting Abstract

    Rencsok, E.; Bazzi, L.; McKay, R.; Huang, F.; Friedant, A.; Vinson, J.; Zarif, J.; Simmons, S.; Villanti, P.; Kantoff, P.; more...
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Meeting Abstract

    Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
    Meeting Abstract

    Sharma, P.; Siefker-Radtke, A. O.; de Braud, F.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J.; Brossart, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    Meeting Abstract

    O'Donnell, P.; Galsky, M. D.; Rosenberg, J. E.; Petrylak, D. P.; Balar, A. V.; McGregor, B. A.; Heath, E.; Yu, E. Y.; Quinn, D. I.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
    Meeting Abstract

    Grivas, P.; Balar, A. V.; Vuky, J.; de Wit, R.; Vogelzang, N. J.; Choueiri, T. K.; Bajorin, D.; Castellano Gauna, D.; Gerritsen, W.; Gurney, H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Fradet, Y.; Climent, M. A.; Petrylak, D. P.; Lee, J. L.; Fong, L.; Necchi, A.; Sternberg, C. N.; Grivas, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab + ipilimumab (N + I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Meeting Abstract

    Albiges, L.; Tannir, N.; Burotto, M.; McDermott, D. F.; Plimack, E. R.; Barthélémy, P.; Porta, C. G.; Powles, T. B.; Donskov, F.; George, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save